Angela Fitch on GLP-1 mental health concerns: Data shows patients' moods get better, not worse Dr
Clone EJl 73/112-Cl 1 (r84) showed the highest binding signal and hence the highest affinity
Whats new is actively prescribing medications whose primary indication is metabolic (obesity, diabetes) but that also have psychiatric effects
Non-diabetic patients prescribed semaglutide have an increased likelihood of delayed gastric emptying and gallstones compared to those on other weight loss medications
For weight management , certain GLP-1 formulations (liraglutide 3.0mg [Saxenda] and semaglutide 2.4mg [Wegovy]) are licensed for chronic weight management in adults with: BMI 30 kg/m , or BMI 27 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or dyslipidaemia) However, NHS access to these medications for weight management is typically restricted to specialist tier 3 or tier 4 weight management services, with specific eligibility criteria defined by NICE technology appraisals (TA494 for liraglutide, TA664 for semaglutide) and local commissioning arrangements
